InvestorsHub Logo
Followers 68
Posts 2644
Boards Moderated 0
Alias Born 08/20/2013

Re: tradingjunk123 post# 657

Monday, 05/29/2017 1:39:59 AM

Monday, May 29, 2017 1:39:59 AM

Post# of 704
I have been adding too. Positive preclinical trial news for XCede and I think this gets some attention, as it almost feels like failure is priced in since it sat on the shelf so long. They have credible partners for the biomedical and we should be hearing results this year. They have done a good job reducing debt, but revenues are lumpy. Optometrics growth should add a few cents per share over the next couple years.